The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2022 | Selinexor: a clear role in heavily pre-treated multiple myeloma
Dan Vogl, MD, MSCE, University of Pennsylvania, Philadelphia, PA, reaffirms the role of selinexor, a selective inhibitor of nuclear export (SINE), for pre-treated patients with multiple myeloma. Speaking at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France, Dr Vogl recalls the Phase III BOSTON trial (NCT03110562), which showed the addition of selinexor with bortezomib and dexamethasone delivered superior response rates and progression-free survival (PFS) vs. bortezomib and dexamethasone alone. Dr Vogl also discusses the combinations available that can be varied depending on the patient.
Disclosures
Consulting fees and research funding from Takeda. Consulting fees from Karyopharm, Janssen, GSK, Sanofi, Oncopeptides, and CSL Behring. Research funding from Active Biotech.
